Protalix's development pipeline that includes the following product candidates: PRX-102, a modified version of the recombinant human alpha-GAL-A protein for the treatment of Fabry disease; PRX-112, an orally-delivered glucocerebrosidase enzyme that is produced and encapsulated within carrot cells, for the treatment of Gaucher disease; pr-antiTNF, a similar plant cell version of etanercept (Enbrel(R)) for the treatment of certain immune and inflammatory diseases, such as rheumatoid arthritis, Crohn's disease, colitis, psoriasis and other autoimmune and inflammatory disorders; PRX-110 for the treatment of Cystic Fibrosis; and others.
The oral Gaucher drug when approved will IMO be beneficial to the patients and share holders.
Sentiment: Strong Buy
I loved the short that closed his position all the way up to $3.00 hold on shorts:) 25% shorted and good news double bottom @ $2.35. Institutional Ownership at 47%. Phase 2A study in progress.
Sentiment: Strong Buy
They have $65+ million dollars cash from the most recent Quarterly report. Complete lie.
it is almost guaranteed that they are trying to get the stock price up to do a secondary. I hung in as long as I could but took my losses and sold. I obviously will be listening to what they have to say but I wont come back in until they have turned the corner.
Well obviously you are a $h!tbag, but your point is valid, if the company only values its shares at that price why pay more?
Best suggestion is to look at the 10-Qs. Sometime in the next few days might be a good idea as the stock is about to take a leg up (a small 5% leg). The Bio-Cell paperwork showed a remaining position of 10,000,000 shares.
Chipster and Bronson,
Thanks. I'm contemplating taking a position here, but there's no way of doing any DD. There's no press releases from the company, IR doesn't answer my emails or calls. Is there info in Hebrew I can use Google translate to translate.
It was paper moving of the shares, the people that received them wanted the shares. They are holding them, Bio-Cell assigned a value for tax purposes and distributed them at that number. Accounting smoke and mirrors nothing more nothing less.
Gaucher market is tiny. Company needs to focus on other diseases.